|
huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D Clinical Trials
1 actively recruiting trial across 1 location
No change since May 2026
Pipeline
Phase 1: 1
Top Sponsors
- Minerva Biotechnologies Corporation1
Indications
- Metastatic Breast Cancer1
- Breast Cancer1
- Cancer1
Duarte, California1 trial
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*)
City of Hope Medical Center
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.